Butantan vaccine (Sinovac) has
100% efficacy in preventing severe and moderate cases. This means no one in the trials ever got moderate and severe cases. With mild cases, the efficacy is 78%.
https://www.reddit.com/r/COVID19/comments/kt076p
Translated from Portugese via Google Translate.
Butantan vaccine reaches 100% effectiveness for moderate and severe cases
Scientific study with 12,400 professionals showed total protection against severe symptoms of COVID-19 and 78% efficiency against mild cases
The Government of São Paulo and the Butantan Institute confirmed on Thursday (7) that the vaccine against the coronavirus developed in partnership with the biopharmaceutical Sinovac Life Science reached an efficacy rate of 100% for severe and moderate cases. The clinical study carried out in Brazil involved the participation of 12,400 volunteer health professionals in 16 research centers.
“Today is a very important day for Brazil, Brazilians, health and life. Instituto Butantan's vaccine is 78% to 100% effective against COVID-19, according to studies in Brazil, ”said Governor João Doria. “As Governor of São Paulo, I want to thank the more than 12 thousand volunteers who agreed to participate in this research coordinated by Butantan and centers of excellence in eight Brazilian states. Also thank the researchers, doctors and scientists who helped and contributed to find this great result. Our recognition and our gratitude. ”
Among those immunized during clinical tests and who contracted the virus, none had a severe or moderate case of the disease or needed hospitalization. In other words, whoever takes the Butantan vaccine will have their health protected and minimal chances of worsening COVID-19.
The efficacy rate was 78% for those infected who had mild cases or needed outpatient care. This means that for every hundred volunteers who contracted the virus, only 22 had only mild symptoms, but without the need for hospitalization.
With the rates reached in the research, Butantan started this Thursday to request the emergency registration of the vaccine with Anvisa (National Health Surveillance Agency), so that the immunization of Brazilians against COVID-19 can be started quickly.
“The vaccine has shown 100% effectiveness against severe and moderate cases. There were no serious cases of COVID-19 among volunteers immunized with the Butantan vaccine, ”explained the institution's director, Dimas Tadeu Covas.
Covas pointed out that the research carried out in Brazil was the hardest and most complex test ever carried out in the world for a coronavirus vaccine and the most detailed study ever presented.
As they are health professionals, all 12,400 volunteers had a much higher risk of infection, as they were at the forefront of care provided to infected patients.
The partnership between Butantan and the China laboratory has been developed since June 10. In October last year, it was announced that Coronavac is the safest among all vaccines tested in Brazil.
In November, Lancet, one of the most important scientific magazines in the world, published Coronavac's safety results in phases 1 and 2, carried out in China, with 744 volunteers. The publication showed that the vaccine is safe and has the capacity to produce an immune response in 97% of cases within 28 days after application.
Production
Butantan concluded the hiring of 124 professionals to reinforce the production of the coronavirus vaccine. The new workers join the 245 who already worked at the site, which occupies a production area of 1,880 square meters. 69 production assistants, 53 production technicians and two technologists were hired.
Of the total number of professionals hired, 37 started working on this farm. The others start activities on the next 14th, after training and integration.
“Our efforts to increase the team of professionals come from Butantan's commitment to quickly make a vaccine available for use in the Brazilian population. As a matter of urgency, we guarantee the third shift of the factory in an incessant production routine. Today, we already have 10.8 million doses on national soil ”, said Dimas Covas.
The packaging area has six main machines for packaging the extract composed of the vaccine sent by the biopharmaceutical Sinovac Life Science, in addition to the labeling and packaging of the immunizer developed in an international partnership signed by the Government of São Paulo and Butantan.
In the same complex, 80 million doses of the flu vaccine are packaged annually, in addition to 13 different types of serums that are used in the public health system. The immunizer has a composition similar to others produced by Butantan, which facilitates and speeds up the filling process.
